<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>These studies describe experimental conditions where aspirin is less effective than other antiplatelet and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> drugs in inhibiting <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>External electrolytic injury of the rat carotid artery was used to induce occlusive <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in 97% of vehicle-treated rats </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">Thrombi</z:e> were revealed by light and electron microscopy to be comprised primarily of platelets enmeshed in a fibrin network </plain></SENT>
<SENT sid="3" pm="."><plain>The thrombin inhibitor <z:chebi fb="0" ids="29996,32500">D-phenylalanyl</z:chebi>-<z:chebi fb="0" ids="32865">L-prolyl</z:chebi>-<z:chebi fb="0" ids="29952,32684">L-arginyl</z:chebi> chloromethylketone (PPACK; 6 mg/kg, i.v.) decreased <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight by 90% </plain></SENT>
<SENT sid="4" pm="."><plain>Aspirin alone (1, 10 and 30 mg/kg, i.v.), <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> alone (5 mg/kg i.v.) and aspirin (1 and 10 mg/kg, i.v.) in combination with <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> (5 mg/kg, i.v.) did not inhibit <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>The platelet-activating factor (PAF) <z:chebi fb="68" ids="48706">antagonist</z:chebi>, WEB 2086, (1 mg/kg i.v.) was also ineffective </plain></SENT>
<SENT sid="6" pm="."><plain>Other drugs had intermediate activity </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">Thrombi</z:e> were decreased 56% by the <z:chebi fb="0" ids="26995">thromboxane</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, BMS 180,291, either alone (5.8 mg/kg i.v.) or in combination with aspirin (10 mg/kg, i.v.) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> (900 U/kg, i.v.), <z:chebi fb="8" ids="10033">warfarin</z:chebi> (0.25 mg/kg, p.o. once daily for 3 days) and <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> (200 mg/kg, p.o. once daily for 3 days) reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight by 63, 73 and 43% respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Reductions in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight were always associated with improvements in either average blood flow or vessel patency </plain></SENT>
</text></document>